Mina Kim1,2, Francisco Torrealdea3, Sola Adeleke4, Marilena Rega5, Vincent Evans4, Teresita Beeston4, Katerina Soteriou4, Stefanie Thust2, Aaron Kujawa1,2, Sachi Okuchi1,2, Elizabeth Isaac4, Wivijin Piga4, Jonathan R Lambert6, Asim Afaq5, Eleni Demetriou1,2, Pratik Choudhary7,8, King Kenneth Cheung9, Sarita Naik10, David Atkinson4, Shonit Punwani4, Xavier Golay1,2. 1. Department of Brain Repair and Rehabilitation, UCL Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London, London, UK. 2. Lysholm Department of Neuroradiology, National Hospital for Neurology and Neurosurgery, London, UK. 3. Medical Physics and Biomedical Engineering, University College Hospital, London, UK. 4. UCL Centre for Medical Imaging, London, UK. 5. Institute of Nuclear Medicine, University College Hospital, London, UK. 6. Department of Haematology, University College London Hospital, London, UK. 7. King's College Hospital NHS Foundation Trust, London, UK. 8. Department of Diabetes, School of Life Course Sciences, King's College London, London, UK. 9. University College London Hospitals NHS Foundation Trust, London, UK. 10. Department of Diabetes and Endocrinology, University College Hospital, London, UK.
Abstract
BACKGROUND: The aim of this study was to translate dynamic glucose enhancement (DGE) body magnetic resonance imaging (MRI) based on the glucose chemical exchange saturation transfer (glucoCEST) signal to a 3 T clinical field strength. METHODS: An infusion protocol for intravenous (i.v.) glucose was optimised using a hyperglycaemic clamp to maximise the chances of detecting exchange-sensitive MRI signal. Numerical simulations were performed to define the optimum parameters for glucoCEST measurements with consideration to physiological conditions. DGE images were acquired for patients with lymphomas and prostate cancer injected i.v. with 20% glucose. RESULTS: The optimised hyperglycaemic clamp infusion based on the DeFronzo method demonstrated higher efficiency and stability of glucose delivery as compared to manual determination of glucose infusion rates. DGE signal sensitivity was found to be dependent on T2, B1 saturation power and integration range. Our results show that motion correction and B0 field inhomogeneity correction are crucial to avoid mistaking signal changes for a glucose response while field drift is a substantial contributor. However, after B0 field drift correction, no significant glucoCEST signal enhancement was observed in tumour regions of all patients in vivo. CONCLUSIONS: Based on our simulated and experimental results, we conclude that glucose-related signal remains elusive at 3 T in body regions, where physiological movements and strong effects of B1 + and B0 render the originally small glucoCEST signal difficult to detect. 2019 Quantitative Imaging in Medicine and Surgery. All rights reserved.
BACKGROUND: The aim of this study was to translate dynamic glucose enhancement (DGE) body magnetic resonance imaging (MRI) based on the glucose chemical exchange saturation transfer (glucoCEST) signal to a 3 T clinical field strength. METHODS: An infusion protocol for intravenous (i.v.) glucose was optimised using a hyperglycaemic clamp to maximise the chances of detecting exchange-sensitive MRI signal. Numerical simulations were performed to define the optimum parameters for glucoCEST measurements with consideration to physiological conditions. DGE images were acquired for patients with lymphomas and prostate cancer injected i.v. with 20% glucose. RESULTS: The optimised hyperglycaemic clamp infusion based on the DeFronzo method demonstrated higher efficiency and stability of glucose delivery as compared to manual determination of glucose infusion rates. DGE signal sensitivity was found to be dependent on T2, B1 saturation power and integration range. Our results show that motion correction and B0 field inhomogeneity correction are crucial to avoid mistaking signal changes for a glucose response while field drift is a substantial contributor. However, after B0 field drift correction, no significant glucoCEST signal enhancement was observed in tumour regions of all patients in vivo. CONCLUSIONS: Based on our simulated and experimental results, we conclude that glucose-related signal remains elusive at 3 T in body regions, where physiological movements and strong effects of B1 + and B0 render the originally small glucoCEST signal difficult to detect. 2019 Quantitative Imaging in Medicine and Surgery. All rights reserved.
Entities:
Keywords:
Glucose chemical exchange saturation transfer (glucoCEST), body magnetic resonance imaging (body MRI); clinical 3 T; field inhomogeneity; magnetization transfer ratio asymmetry (MTRasym)
Authors: Patrick Schuenke; Johannes Windschuh; Volkert Roeloffs; Mark E Ladd; Peter Bachert; Moritz Zaiss Journal: Magn Reson Med Date: 2016-02-09 Impact factor: 4.668
Authors: Daniel Paech; Patrick Schuenke; Christina Koehler; Johannes Windschuh; Sibu Mundiyanapurath; Sebastian Bickelhaupt; David Bonekamp; Philipp Bäumer; Peter Bachert; Mark E Ladd; Martin Bendszus; Wolfgang Wick; Andreas Unterberg; Heinz-Peter Schlemmer; Moritz Zaiss; Alexander Radbruch Journal: Radiology Date: 2017-06-16 Impact factor: 11.105
Authors: Xiang Xu; Kannie W Y Chan; Linda Knutsson; Dmitri Artemov; Jiadi Xu; Guanshu Liu; Yoshinori Kato; Bachchu Lal; John Laterra; Michael T McMahon; Peter C M van Zijl Journal: Magn Reson Med Date: 2015-09-25 Impact factor: 4.668
Authors: Anina Seidemo; Patrick M Lehmann; Anna Rydhög; Ronnie Wirestam; Gunther Helms; Yi Zhang; Nirbhay N Yadav; Pia C Sundgren; Peter C M van Zijl; Linda Knutsson Journal: NMR Biomed Date: 2021-09-29 Impact factor: 4.478
Authors: Mina Kim; Afroditi Eleftheriou; Luca Ravotto; Bruno Weber; Michal Rivlin; Gil Navon; Martina Capozza; Annasofia Anemone; Dario Livio Longo; Silvio Aime; Moritz Zaiss; Kai Herz; Anagha Deshmane; Tobias Lindig; Benjamin Bender; Xavier Golay Journal: MAGMA Date: 2022-01-15 Impact factor: 2.310